AVBP
ArriVent BioPharma, Inc. Common StockNASDAQHealthcare$24.89+2.77%ClosedMarket Cap: $1.10B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.12
P/S
0.00
EV/EBITDA
-6.13
DCF Value
$1.04
FCF Yield
-14.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-62.5%
ROA
-49.9%
ROIC
-57.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-38.8M | $-35.5M | $-0.84 | — |
| FY 2025 | $0.00 | NaN% | $-177.5M | $-166.3M | $-4.32 | — |
| Q3 2025 | $0.00 | NaN% | $-38.3M | $-35.0M | $-0.83 | — |
| Q2 2025 | $0.00 | NaN% | $-33.6M | $-31.4M | $-0.90 | — |
| Q1 2025 | $0.00 | NaN% | $-66.8M | $-64.4M | $-1.90 | — |
| Q4 2024 | $0.00 | NaN% | $-23.7M | $-20.6M | $-0.61 | — |
| FY 2024 | $0.00 | NaN% | $-94.3M | $-80.5M | $-2.56 | — |
| Q3 2024 | $0.00 | NaN% | $-24.2M | $-20.6M | $-0.61 | — |
| Q2 2024 | $0.00 | NaN% | $-25.7M | $-21.9M | $-0.65 | — |
| Q1 2024 | $0.00 | NaN% | $-20.7M | $-17.4M | $-0.52 | — |
| Q4 2023 | $0.00 | NaN% | $-23.1M | $-21.2M | $-0.63 | — |
| FY 2023 | $0.00 | NaN% | $-74.6M | $-69.3M | $-2.17 | — |